| Literature DB >> 2694416 |
P S Imperia1, H M Lazarus, J H Lass.
Abstract
Cancer chemotherapy has changed rapidly in recent years. New agents are constantly being developed. Established agents are being used with increased frequency, in new combinations, at higher dosages, and via new routes of administration. Enhanced survival, as well as increased drug toxicity, has resulted. Ocular toxicity is not uncommon and can greatly impact on quality of life. Practitioners in all fields are increasingly caring for patients who are receiving cancer chemotherapy. The recognition of eye disease resulting from chemotherapy is essential to appropriate patient management. We provide a review of the rapidly growing body of literature on the ocular toxicity of systemic cancer chemotherapy with particular attention to context, clinical course, mechanism, prevention and treatment.Entities:
Mesh:
Substances:
Year: 1989 PMID: 2694416 DOI: 10.1016/0039-6257(89)90105-7
Source DB: PubMed Journal: Surv Ophthalmol ISSN: 0039-6257 Impact factor: 6.048